Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaime O Herrera-Caceres

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Opinion in Urology|April 27, 2018
Roles for active surveillance in renal cancerJaime O Herrera-Caceres, Michael A S Jewett
Archivos Espanoles De Urologia|March 12, 2019
Active surveillance in intermediate risk prostate cancerThenappan Chandrasekar, Jaime O Herrera-Caceres, Laurence Klotz
Current Opinion in Urology|December 12, 2018
Future developments in ureteral stentsClemens G Wiesinger, Jason Lee, Jaime O Herrera-Caceres
World Journal of Urology|July 20, 2018
Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision managementJaime O Herrera-Caceres, Antonio Finelli, Michael A S Jewett
The Lancet. Oncology|April 30, 2022
Patient-reported outcomes: what really matters to patients?Elshad Hasanov, Jaime O Herrera Caceres, Deborah A Maskens, et al.
Cancer Medicine|March 13, 2020
Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?Marian S Wettstein, David Naimark, Thomas Hermanns, et al.
Cancer|December 19, 2018
The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entityThenappan Chandrasekar, Hanan Goldberg, Zachary Klaassen, et al.
Immunology Letters|July 23, 2013
Genetic variations in toll-like receptor 4 in Mexican-Mestizo patients with intra-abdominal infection and/or pneumoniaCarlos A Rodriguez-Osorio, Guadalupe Lima, Jaime O Herrera-Caceres, et al.
Urologic Oncology|May 10, 2022
Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomesYazan Qaoud, Jaime O Herrera-Caceres, Roman Bass, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 2, 2020
Predictors of prostate-specific antigen testing in men aged ≥55 years: A cross-sectional study based on patient-reported outcomesJoon Yau Leong, Thenappan Chandrasekar, Alejandro Berlin, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Opinion in Urology|April 27, 2018
Roles for active surveillance in renal cancerJaime O Herrera-Caceres, Michael A S Jewett
Archivos Espanoles De Urologia|March 12, 2019
Active surveillance in intermediate risk prostate cancerThenappan Chandrasekar, Jaime O Herrera-Caceres, Laurence Klotz
Current Opinion in Urology|December 12, 2018
Future developments in ureteral stentsClemens G Wiesinger, Jason Lee, Jaime O Herrera-Caceres
World Journal of Urology|July 20, 2018
Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision managementJaime O Herrera-Caceres, Antonio Finelli, Michael A S Jewett
The Lancet. Oncology|April 30, 2022
Patient-reported outcomes: what really matters to patients?Elshad Hasanov, Jaime O Herrera Caceres, Deborah A Maskens, et al.
Cancer Medicine|March 13, 2020
Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?Marian S Wettstein, David Naimark, Thomas Hermanns, et al.
Cancer|December 19, 2018
The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entityThenappan Chandrasekar, Hanan Goldberg, Zachary Klaassen, et al.
Immunology Letters|July 23, 2013
Genetic variations in toll-like receptor 4 in Mexican-Mestizo patients with intra-abdominal infection and/or pneumoniaCarlos A Rodriguez-Osorio, Guadalupe Lima, Jaime O Herrera-Caceres, et al.
Urologic Oncology|May 10, 2022
Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomesYazan Qaoud, Jaime O Herrera-Caceres, Roman Bass, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 2, 2020
Predictors of prostate-specific antigen testing in men aged ≥55 years: A cross-sectional study based on patient-reported outcomesJoon Yau Leong, Thenappan Chandrasekar, Alejandro Berlin, et al.
Pageof 3